AzTrials
AzTrials

Carotid ArteriosclerosisRECEPTNCT07057297

Residual Stenosis and Restenosis Following Carotid Endarterectomy With Primary Closure, A Prospective Tracking Study

An observational study of Carotid Arteriosclerosis and Carotid Stenosis, run by Charles University, Czech Republic at 1 site in Czechia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary closure. Read more about this study

Who is it for?
Ages 18 to 90 years
How many people
300 participants
Where
1 siteCzechia
Study dates
1 Feb 2025to 1 Jan 2027
How long will I take part?
1 Year
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who undergo carotid endarterectomy for carotid artery stenosis with primary suture.

Who may be able to join

  • Patients without matching any of exclusion criteria who underwent cartotid endarterectomy

Who cannot join

  • Age ≤18 or ≥90 years
  • Previous endarterectomy or stenting
  • Unsuitable vascular anatomy
  • High perioperative risk
  • Contralateral cranial nerve X or XII palsy
  • History of neck irradiation
  • Tandem carotid stenosis or intracranial vascular pathology (e.g., aneurysm or AVM)
  • Absence of signed informed consent

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

norbert Svoboda, MD contact

+420973202963

norbert.svoboda@uvn.cz

Czechia1 site, 1 recruiting
  • Central Military Hospital Prague

    Prague, 16200

    Norbert Svoboda, MD, +420973202963, norbert.svoboda@uvn.cz

    David Netuka, Prof., ++420973202963, david.netuka@uvn.cz

    Recruiting

Other trials in Czechia

About this study

This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary closure. Conducted across several neurosurgical centers in the Czech Republic, the study will include patients undergoing elective CEA who meet standard clinical indications.

Participants will undergo preoperative CT angiography and follow-up imaging at 30 days and 1 year post-surgery. Residual stenosis is defined as ≥50% luminal narrowing detected within 30 days postoperatively, while restenosis is evaluated at later time points. The study will also assess clinical outcomes such as ischemic stroke, TIA, myocardial infarction, and mortality. The standardized surgical technique and harmonized diagnostic algorithm across all centers aim to provide robust data on the performance and durability of primary closure CEA.

Read the detailed description

Study Objective:

The objective of this study is to assess the true incidence of restenosis following CEA in the Czech Republic. A major advantage of this study is the use of standardized surgical procedures across participating centers, along with unified data collection methods and diagnostic algorithms.

Methodology:

Patient Cohort:

All patients meeting the current guideline indications for CEA will be enrolled.

Exclusion criteria include:

Age ≤18 or ≥90 years

Previous endarterectomy or stenting

Unsuitable vascular anatomy

High perioperative risk

Contralateral cranial nerve X or XII palsy

History of neck irradiation

Tandem carotid stenosis or intracranial vascular pathology (e.g., aneurysm or AVM)

Absence of signed informed consent

Collected data will include:

Epidemiologic risk factors: age, sex, diabetes, hypertension, dyslipidemia, metabolic syndrome, renal insufficiency, smoking, physical activity, weight, comorbidities

Laboratory markers: LDL, HDL, cholesterol, lipoprotein A, triglycerides, CKD-EPI, sedimentation rate, fibrinogen, INR (Quick test), APTT

Diagnostics:

All patients will undergo non-contrast brain CT. Carotid stenosis will be assessed by CT angiography performed within 3 months prior to surgery. In addition to stenosis severity, the degree of calcification will be classified as:

No calcification

Minimal

Partially calcified

Pronounced

Severe/unable to evaluate

Other vascular pathology will also be recorded. Follow-up imaging will be performed at 1 month and 1 year postoperatively. CT findings will be assessed by two independent reviewers.

Surgical Technique:

All patients will receive mono- or dual antiplatelet therapy, and 5,000 IU of heparin will be administered intraoperatively. Surgery may be performed under general anesthesia with electrophysiological monitoring or under local anesthesia, based on the surgeon's preference.

A longitudinal incision will be made anterior to the sternocleidomastoid muscle. The common carotid artery and its branches will be dissected and clamped. The internal carotid artery will be clamped distal to the most significant stenosis, as identified on preoperative CTA. The surgeon will incise through the tunica adventitia and media to expose and excise the atherosclerotic plaque. Any residual fragments will be removed, and the arterial wall will be closed using 6/0 suture.

Follow-Up:

Patients will continue on mono- or dual antiplatelet therapy. Mandatory follow-up CT angiography will be performed at 30 days and1 year. During follow-up, the following will be evaluated:

CTA findings

Overall patient condition

Incidence of ischemic stroke (iCMP), TIA, myocardial infarction, and death

Outcomes:

Primary Outcome:

Restenosis ≥50% at 12 months

Secondary Outcomes:

Residual stenosis ≥50% at 30 days

iCMP/TIA/death/MI

Change in modified Rankin Scale (mRS)

Timeline:

All participating centers (ÚVN, ČB, ÚNL, Poruba, Plzeň, Liberec, Zlín, Olomouc, Hradec Králové, Fifejdy, Ostrava) together treat approximately 600-700 patients annually.

An estimated 350 patients will be enrolled within 6 months. By the end of 2026, 300 patients will be included (expected dropout: 50).

This will allow evaluation of:

Secondary outcomes in all 300 patients

Primary outcome in approximately 8 out of 26 centers (those with complete 12-month data)

Ethical Approval:

All participating centers have received approval from their respective institutional ethics committees.

Funding:

This study is conducted without external financial support.

Keywords
Carotid Artery, Atherosclerosis, Endarterectomy, Stroke
Medical subject headings
Carotid Artery Diseases, Carotid Stenosis, Atherosclerosis, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07057297
Study groupRoleWhat they receive
Patients after carotid endarterectomyIncluded paitnets with sign informed consent after carotid endarterectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Restenosis ≥50% at 12 months

    Restenosis ≥50% at 12 months

    Measured: 12 months

Secondary outcomes (3)
  1. Restenosis ≥50%

    Restenosis ≥50%

    Measured: 30 days

  2. iCMP/TIA/death/MI

    iCMP/TIA/death/MI

    Measured: 1 year

  3. Change in modified Rankin Scale (mRS)

    Change in modified Rankin Scale (mRS)

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jul 2025
  2. Study start1 Feb 2025
  3. Primary completion1 Jan 2026 (estimated)
  4. Study completion1 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT07057297
Sponsor's protocol ID
108/19-31/2024
Acronym
RECEPT
Status last verified
Jun 2025
First submitted
30 Jun 2025
Last updated
9 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Epidemiologic risk factors: age, sex, diabetes, hypertension, dyslipidemia, metabolic syndrome, renal insufficiency, smoking, physical activity, weight, comorbidities Laboratory markers: LDL, HDL, cholesterol, lipoprotein A, triglycerides, CKD-EPI, sedimentation rate, fibrinogen, INR (Quick test), APTT

Questions about this trial

What is this clinical trial studying?

An observational study of Carotid Arteriosclerosis and Carotid Stenosis, run by Charles University, Czech Republic at 1 site in Czechia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact norbert Svoboda, MD (+420973202963, norbert.svoboda@uvn.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Restenosis ≥50% at 12 months (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in